Faust, Saul - University of Southampton

研究领域

Clinical biofilm research Professor Faust is clinical lead for the University of Southampton Institute for Life Sciences Biofilm and Microbial Communities Research Group. Together with colleagues from the Faculty of Medicine (Stuart Clarke, Rami Salib), Faculty of Natural and Environmental Sciences (Jeremy Webb, Bill Keevil) and the National Centre for Advanced Tribology in the Faculty of Engineering (Paul Stoodley), the group have developed a range of methods based in the Southampton NIHR Wellcome Trust Clinical Research Facility (WTCRF) and University laboratories, including direct and confocal microscopy, live/dead stain and analysis, colony forming unit assessment, fluorescent in-situ hybridisation (FISH) and quantitative PCR, that together act as novel microbiological biomarkers to assess the response of ex-vivo biofilms before, during and after the use of novel treatments in clinical trials, and to better diagnose and understand biofilm-related diseases. As part of the Southampton National Institute for Health Research Respiratory Biomedical Research Unit we are currently investigating novel adjunctive therapies in cystic fibrosis, paediatric otitis media, adult CRS, catheter-related intravascular line infections and ventilator-associated pneumonias, as well as working on orthopaedic implant and wound infections. Paediatric clinical trials Professor Faust leads and participates in clinical trials aimed at understanding disease and improving the clinical management of paediatric infections and acts as Southampton principal investigator on a number of NIHR non-commercial and commercial portfolio clinical trials. Paediatric and adult vaccine trials Professor Faust has established the Southampton NIHR WTCRF as one of the main academic paediatric vaccine centres that form the UK Paediatric Vaccine Group. In collaboration with colleagues at Oxford, Bristol and St Georges London he shares the leadership, design, and delivery of multicentre vaccine trials and acts as Southampton PI for NIHR commercial portfolio paediatric and adult vaccine research. Professor Faust also collaborates with the Oxford Jenner Institute to enroll Southampton adults in early phase trials of novel influenza and malaria vaccines and with Professor Robert Read in Southampton to develop bacterial and viral challenge models and develop new vaccines. With Stuart Clarke (Clinical and Experimental Sciences), Professor Faust leads the paediatric clinical component of longitudinal molecular epidemiological bacterial carriage studies to inform vaccine policy and design. Paediatric Recurrent Infection and Immunodeficiency Together with Tony Williams (Cancer Sciences), Professor Faust co-leads a programme of work investigating novel innate immune defects in children and families with recurrent infections but no defined immunodeficiency. The group have combined new investigative approaches that assess immune competency in innate immune pathways with participation in national and international collaborations. Clinical Research Management and Governance As the Southampton NIHR WTCRF Director, Professor Faust ensures the CRF acts as the operational focus of the Southampton Centre for Biomedical Research, working with colleagues across the University and University Hospital Southampton Foundation Trust to ensure easy access to research facilities for all investigators and maximum efficiency and economy of scale across the translational research infrastructure.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Cephalosporin-3’ -diazeniumdiolate NO-donor prodrug PYRRO-C3D enhances azithromycin susceptibility of Non-typeable Haemophilus influenzae biofilms - Collins, Samuel A., Kelso, Michael J., Rineh, Ardeshir, Yepuri, Nageshwar R., Coles, Janice, Jackson, Claire L., Halladay, Georgia D., Walker, Woolf T., Webb, Jeremy S., Hall-Stoodley, Luanne, Connett, Gary J., Feelisch, Martin, Faust, Saul N., Lucas, Jane S.A. and Allan, Raymond N. Published:2016Publication:Antimicrobial Agents and ChemotherapyPage Range:1-16doi:10.1128/AAC.02086-16PMID:27919896 Pneumococcal conjugate vaccine implementation in middle-income countries - Tricarico, Serena, McNeil, Hannah C., Cleary, David W., Head, Michael G., Lim , Victor, Kok Seng Yap, Ivan, Chun Wie, Chong, Siang Tan, Cheng, Norazmi, Mohd Nor, Ismail, Aziah, Seong Guan Cheah, Eddy, Faust, Saul N., Jefferies, Johanna M.C., Roderick, Paul J., Moore, Michael, Yuen, Ho Ming, Newell, Marie-Louise, Mcgrath, Nuala, Webb, Jeremy, Doncaster, C. Patrick, Kraaijeveld, Alex R., Webb, Jeremy S. and Clarke, Stuart C. Published:2016Publication:PneumoniaPage Range:1-26 Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy - Pace, David, Khatami, Ameneh, Attard-Montalto, Simon, Voysey, Merryn, Finn, Adam, Faust, Saul N., Heath, Paul T., Borrow, Ray, Snape, Matthew D. and Pollard, Andrew J. Published:2016Publication:VaccinePage Range:1-8doi:10.1016/j.vaccine.2016.10.038